BRAF and melanoma: Atx PA and Atx LF have shown interesting intrinsic anti-tumor properties because they inhibit MAPKK-associated pathways, for example, in melanoma bearing the V600E BRAF mutation [102,103] and in melanoma xenografts by killing endothelial cells [104].